Pharma — India Patent Cases
1,090 decisions indexed
Page 5 of 37 · 1,090 total
Mankind Pharma Limited v.Caremankind Hospital Private Limited
Mankind Pharma Limited successfully secured an interim injunction against Caremankind Hospital Private Limited in the Delhi High Court. The court found a prima facie case for infringement and passing off, noting that the defendant was using identical or deceptively similar marks ('MANKIND'/'CAREMANKIND') in relation to similar services. This crucial early ruling protects Mankind Pharma's established brand equity while the main suit proceeds.
Adventia Pharma, S.L & Anr. v.The Assistant Controller of Patents and Designs
Adventia Pharma appealed against the Assistant Controller's order dated January 29, 2025, which refused to grant a patent for Indian Patent Application No. 202117035025. The court allowed applications for exemption and condonation of delay before directing parties to file synopsis and list the case.
Zydus Healthcare Ltd v.Shahid Ahmad Mir
In a significant resolution for the pharmaceutical sector, Zydus Healthcare Ltd successfully concluded its dispute with Shahid Ahmad Mir through a comprehensive settlement decree. The parties agreed that Defendant would cease all use of marks or packaging deceptively similar to 'PROTIMED.' Crucially, the defendant formally transferred all rights and goodwill associated with the registered trademark 'PROTIMED' (No. 2159273) to Zydus for a consideration of Rs. 5,00,000, effectively resolving the infringement claim.
Oramed Ltd. v.The Controller General Of Patents And Designs & Anr.
Oramed Ltd. appealed against an order refusing patent grant for its oral insulin composition. The appeal contended that the Deputy Controller made arbitrary omissions of prior art documents and ignored crucial technical data and expert testimony when assessing inventive steps under Section 3(e) of the Patents Act, 1970.
Msn Laboratories Private Limited v.Array Biopharma, Inc & Anr.
The petitioner filed a petition seeking revocation of Indian Patent No. IN304285 ('ERBB Inhibitors') granted to Respondent No. 1 under Section 64 of the Patents Act, 1970. The court also addressed several interlocutory applications regarding filing documents and extensions of time.
Srinivas Jegannathan v.The Controller of Patents
The appellant challenged the Controller's order rejecting Patent Application No. 122/CHE/2006 for a novel antibiotic formulation (Ceftazidime, Tazobactum, and Linezolid). The appellant argued that the combination was not obvious from prior art. The High Court set aside the rejection order and remanded the matter for reconsideration based on the original claims.
Shaperon Inc. v.The Controller General Of Patents And Designs, Mumbai and Anr.
Shaperon Inc. appealed an order passed by the Deputy Controller of Patents & Designs, Kolkata, challenging its validity. The appellant contended that the Deputy Controller failed to consider crucial expert evidence provided by Dr. Seung-yong Seong regarding the invention's technical advancement and advantages. The High Court found the impugned order unsustainable due to this procedural lapse.
ARDENIA INVESTMENTS, LTD. v.CONTROLLER GENERAL OF PATENTS, DESIGNS AND TRADEMARKS AND ANR
This case involves an appeal filed by Ardenia Investments Ltd. against a previous order dismissing its patent application for a "Drug Delivery System for administration of poorly Water Soluble pharmaceutical Active Substances." The original dismissal held that the subject matter lacked technical advancement and inventive steps, specifically citing Section 3(d) of the Act. The Calcutta High Court has issued procedural directions to the appellant regarding the continuation of the appeal.
M/s. Dr.J.R.K's Research and Pharmaceuticals Private Limited v.The Registrar of Trademarks
The Madras High Court ruled in favor of M/s. Dr.J.R.K's Research and Pharmaceuticals Private Limited, directing the Registrar of Trademarks to accept and process a renewal application for the mark 'NATURE'S WEALTH RESTORES HEALTH.' The court held that as long as the trade mark has not been formally removed from the register, the proprietor is entitled to seek renewal, setting aside the rejection order issued by the Registry. This decision provides crucial protection against administrative hurdles preventing legitimate trademark renewals.
Reata Pharmaceuticals Inc v.Deputy Controller Of Patents And Design
Reata Pharmaceuticals Inc appealed the Deputy Controller's order rejecting its patent application for 'NOVEL FORMS Of CDDO METHYL ESTER' on grounds of non-patentability under Sections 3(d) and 3(e). The appellant argued that the rejection failed to consider crucial clinical trial data demonstrating enhanced therapeutic efficacy. The High Court set aside the impugned order, holding that the authority must deal with all submitted evidence and provide reasoned orders.
Sanofi - Aventis v.Controller General Of Patents, Designs and Trademarks
Sanofi - Aventis challenged an order passed by the Assistant Controller Patent and Designs, which rejected their subject invention under Sections 2(i)(j)(a) and 3(c) of the Patents Act, 1970. The Calcutta High Court took cognizance of this appeal (Oa/11/2019/Pt/Kol). While the Respondent Controller remained unrepresented, the court directed Sanofi - Aventis to ensure proper service on the Controller and file an Affidavit of Service before listing the matter for further hearing.
Novartis Ag & Anr v.Intas Pharmaceuticals Limited
The plaintiffs filed a suit seeking a permanent injunction and damages for the infringement of their registered Indian patent (No. 283133) related to Ribociclib. The court subsequently heard various interlocutory applications, including those regarding discovery, exemption from mediation, and an application for interim stay.
Novartis Ag v.Alembic Pharmaceuticals Limited
Novartis Ag filed a suit seeking permanent injunction and damages for infringement of its registered Indian patent (IN 283133) related to Ribociclib. The court proceeded with various interlocutory applications, including those regarding discovery and stay, while the defendant submitted that it is only engaged in permissible research and development.
Astellas Pharma Inc & Anr. v.Lucius Pharmaceutical Lucius Pharmaceuticals Lao Co Ltd & Ors.
Astellas Pharma Inc and its associates filed a suit seeking permanent injunction against Lucius Pharmaceutical for infringing their Indian Patent No. 292990, which covers the new chemical entity GILTERITINIB. The court examined the prima facie case and balance of convenience before granting an ad interim ex-parte injunction. This order restrained the defendants from manufacturing, selling, or distributing any product infringing the patent, including under the brand name LUCIGIL.
Celagenex Research India Pvt Ltd v.Pharmak & Anr.
The plaintiff filed a suit seeking permanent injunction against the defendants for infringing its suit patents. The court examined the composition of the impugned products and found that they used exactly the same salt compositions as the plaintiffs' patented formulations. Consequently, the court granted an ex parte ad-interim injunction.
Glaxosmithkline Pharmaceuticals Limited v.Varav Biogenesis Private Limited And Ors
The Delhi High Court addressed several interlocutory applications in the trademark infringement suit filed by Glaxosmithkline Pharmaceuticals against Varav Biogenesis Private Limited. The court permitted the plaintiff to file additional documents, including sales figures for its 'COBADEX' mark, in a sealed cover. Crucially, the court also initiated proceedings regarding the core dispute, noting that the plaintiff alleges the defendants are using the deceptively similar mark 'CODODEX' for medicinal products, seeking permanent injunction against trademark infringement and passing off.
Novo Nordisk As v.Dr. Reddys Laboratories Limited & Anr.
Novo Nordisk filed a commercial suit against Dr. Reddys Laboratories Limited regarding the manufacture and sale of an 'impugned drug'. The court addressed various interlocutory applications related to filing documents and pre-institution mediation. In relation to the main suit, the defendants stated they had a license to manufacture but not sell in India, while the plaintiff argued that export of infringing products also constitutes infringement.
Glaxo Group Limited And Anr. v.Dinesh Sirvi And Ors
In a trademark infringement suit concerning pharmaceutical products 'Augsomention' and 'Sheoical-nx CCM,' the Delhi High Court issued several orders. The court exempted the plaintiffs from pre-litigation mediation while granting them liberty to file confidential sales documents in sealed cover for protection. Crucially, after both parties agreed to refer their dispute to mandatory mediation, the court granted an interim injunction restraining the defendants from using the disputed marks until a settlement is reached.
Zeria Pharmaceutical Co. Ltd v.The Controller Of Patents
Zeria Pharmaceutical appealed the refusal of its patent application for a novel intermediate compound (formula 5a). The Controller refused the grant, citing lack of novelty and inventive step under Section 2(1)(ja), and falling within the scope of Section 3(d) due to prior art disclosures. The High Court upheld the Controller's decision.
Dr. Reddys Laboratories Limited v.Wockhardt Limited And Anr.
Dr. Reddys Laboratories filed a petition in the Delhi High Court seeking the cancellation of the trademark registration 'PACTYON' held by Wockhardt Limited. The respondents objected to the maintainability of the suit, arguing that the mark was registered in Mumbai. The court accepted notice and set procedural timelines for filing replies and rejoinders, indicating that the matter will proceed through standard litigation steps.
Sun Pharmaceutical Industries Ltd. v.Oziel Pharmaceuticals P. Ltd. & Anr.
The Delhi High Court allowed a joint application for a consent decree in the dispute between Sun Pharmaceutical Industries Ltd. and Oziel Pharmaceuticals P. Ltd. The parties reached an amicable settlement regarding trademark infringement concerning 'PEPFIZ' and 'MINOZ'. Key terms include Defendants recognizing Plaintiff's exclusive rights, agreeing to cease use of deceptively similar marks like 'PEPFIX' and 'MINOZIL', and changing the product name from 'MINOZIL' to 'MINODYL'. The court partially decreed the suit based on these binding settlement terms.
Taiho Pharmaceutical Co Ltd v.The Controller Of Patents
Taiho Pharmaceutical appealed a refusal order by the Controller of Patents regarding its application for a novel piperidine compound. The rejection was based on lack of inventive step and non-patentability under Section 3(d), citing prior art D1. The High Court found that the Controller failed to identify a specific 'known substance' from the Markush structure in D1, making the rejection unsustainable.
Daiichi Sankyo Company, Limited v.Malvinder Mohan Singh And Ors
The Delhi High Court addressed several applications concerning the sale of trademarks ('Religare', 'SRL', and 'Fortis') owned by a Judgment Debtor. While some parties conceded no objection to the sale, others vehemently opposed it due to existing charges or lack of information. The court granted time extensions to opposing parties to file affidavits detailing their stance on the trademark sales, ensuring all stakeholders are heard before proceeding with any auction.
Himalaya Global Holdings Ltd v.Jeena Sikho Lifecare Limited
The Delhi High Court issued a significant order in the trademark infringement suit filed by Himalaya Global Holdings Ltd against Jeena Sikho Lifecare Limited. The court permitted the plaintiffs to file additional documentation and, crucially, addressed the request for an ad interim injunction. While noting concerns over mark similarity and color combination usage, the court granted conditional relief, requiring the defendant (D-1) to change its packaging colors within two weeks while allowing it to exhaust existing stock.
Mankind Pharma Limited v.Zhejiang Yige Enterprise Management Group Co Ltd
Mankind Pharma Limited appealed a decision by the Deputy Registrar of Trade Marks regarding an opposition filed against the trademark 'FLORASIS'. The Delhi High Court granted condonation of a 7-day delay in filing the appeal, allowing the matter to proceed. Notice has been issued to all parties, setting the stage for a substantive hearing on the merits of the trademark dispute.
Viiv Healthcare Company And Anr v.Dy Controller Of Patents And Designs And Ors.
Viiv Healthcare Company appealed a decision by the Deputy Controller rejecting its patent application (IN 3865/KOLNP/2007) for HIV integrase inhibitors, Dolutegravir and Cabotegravir. The court found the rejection order unsustainable due to misinterpretation of previous orders and noted an exceptional delay in the process. Consequently, the appeal was allowed, directing fresh adjudication by another Controller.
M/S Green Star Pharma Llp v.Ved Prakash Trading As Green Star Pharma
This Delhi High Court order addresses an appeal filed by M/S Green Star Pharma Llp against the Commercial Court's dismissal of its interim injunction application. The core dispute revolves around the use of the 'GREEN STAR' trademark in the pharmaceutical sector. While the appellant relies on passing off, the court raises significant questions regarding the timing and scope of goodwill acquisition, especially given the respondent's earlier registered device mark.
Dr. Reddys Laboratories Limited v.Novo Nordisk A/S
Dr. Reddys Laboratories Limited filed a petition seeking the revocation of Indian Patent No. IN 262697 before the Delhi High Court. The court issued notice to the respondents (Novo Nordisk A/S) and set timelines for filing replies, while also disposing of several interlocutory applications related to procedural matters.
Viiv Healthcare Company And Anr v.Dy Controller Of Patents And Designs And Ors.
Viiv Healthcare Company appealed a decision by the Deputy Controller rejecting its patent application (IN 3865/KOLNP/2007) for HIV integrase inhibitors Dolutegravir and Cabotegravir. The appeal challenged the rejection order, citing exceptional delays in the patent process. The court allowed the appeal, setting aside the impugned order.
Vertex Pharmaceuticals Incorporated v.Alivus Life Sciences Limited
The plaintiff filed a suit seeking permanent injunction and damages for infringement of Indian Patent No. IN 282654 related to Ivacaftor. The court initially allowed the exemption from pre-litigation mediation, and subsequently passed an interim order granting ex-parte injunctions against the defendant regarding the use and sale of the patented product.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.